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Muscle and bone 
weakening
Dysregulation of the 
immune system
Elevated kidney stone 
risk
Fluid Redistribution to 
upper body
Elevated radiation 
may increase 
cancer risk
Plasma volume 
decreases, anemia Otoliths in inner 
ear respond 
differently, eyes 
become main 
way to sense 
motion
Spaceflight Effects on Human Physiology

Applied Immunology
Skylab Data - 1973
Humoral immunity
-Immunization with antigen generates 
normal antibody response during flight
(MIR-18)
Post-flight observations
-Altered circulating leukocyte 
distribution
Altered cytokine production 
patterns (secreted, intracellular, 
Th1/Th2)
-Decreased NK cell function
-Decreased granulocyte function
-Decreased T cell function*
-Altered immunoglobulin levels
-Latent viral reactivation
-Altered virus-specific immunity
-Expression of EBV IE/late genes*
-Altered neuroendocrine 
responses
Reduced cell mediated immunity
-CMI Multitest, common recall 
antigens, long duration flight
In-flight cell culture
-Intracellular signaling, cytoskeleton 
rearrangement, microtubule organizing 
center orientation, generalized proliferative 
responses all altered during flight.
Short duration
Long duration
*Post-flight observations differ between 
long vs. short duration space flight.
Reactivation of latent herpesviruses
-EBV, CMV, VZV reactivation during flight
-Infectious VZV particles secreted in saliva
Summary of pre-ISS Evidence

Samples - Timepoints
ISS Sample Types:
• Blood
• Saliva (Liquid)
• Saliva (Dry)
• Urine
• Health Survey
Early
~2 weeks
Mid
2-4 mos
Late
R-1-2 days
L-180 L-45 R+0 R+30
Preflight In-flight Postflight
ISS Sample Schedule:
JSC 
Immunology 
Laboratory
Mercer 
University
Microgen 
Laboratories
JSC Microbiology 
Laboratory
• Latent herpesvirus 
reactivation (saliva/urine)
• Leukocyte subsets
• Intracellular cytokine profiles (4hr 
culture)
•T cell function (24h culture)
•Mitogen-stimulated cytokine 
profiles (48h culture)
•Virus specific T cell number
•Virus specific T cell function
•Plasma cytokine balance
• Leukocyte cytokine RNA
•Stress hormone levels
•Circadian rhythm alignment
PHYSIOLOGICAL 
STRESS
Immune System 
Changes
Adverse clinical 
outcomes
(Latent Viral Reactivation)(Status and Function)
Assays
Flight Hardware

Peripheral leukocyte distribution, T cell function, mitogen-stimulated cytokine 
profiles are all persistently dysregulated for the duration of a 6-month ISS mission.
Appears to be a pan-suppression of adaptive function, including viral specific T 
cells.
Latent herpesviruses, including VZV, persistently reactivate for the duration of a 6-
month ISS mission.
Circadian misalignment occurs, difficult to regain a ‘normal’ circadian rhythm.  
(Sleep meds most commonly prescribed Rx)
Integrated Immune – Conclusions
‘n’ = 22 ISS Astronauts
• A definitive tabulation in the literature is lacking, although various 
NASA activities have created incidence numbers (Clinical Finding 
Forms, etc.)
• Inability to confirm diagnoses
• Restricted to electronic examination
• Treatment options limited
• Data privacy restricted
• Missions vary in workload, stress
• Surgeons may record data differently
• Crew may be reluctant to report medical events
Clinical Incidence onboard ISS?
• Crew weekly PMC records found within the EMR (Electronic Medical Record) were 
reviewed.
• Reported symptoms were evaluated for correlation to the listed adverse event 
categories.  
• There could be multiple events for individual crewmembers.  Events were not double 
scored into multiple categories. 
• Data tabulated from 37 long-duration ISS crewmembers (Exp. 1-28/29; totals 16.63 
person flight years)
• This data represents a standard epidemiological survey of the EMR, reports symptoms 
not diagnosis
Generation of ISS Incidence Numbers – Immunology Scrub
Total Events/
events person year
Allergic Reaction 1 0.06
Anaphylaxis 0 ---
Upper Respiratory Infection (combination of rhinitis, nasal 
stuffiness and sneezing)
5 0.301
Eye Infection 0 ---
Herpes Zoster 5 0.301
Otitis Media/Externa (ear pain, or ear stuffiness+congestion) 17 1.022
Pharyngitis (sore throat) 1 0.06
Sepsis 0 ---
Sinus Infection 0 ---
Skin Infection (including scalp pruritis, pus forming wounds on 
wrist, finger)
5 0.301
Skin Rash/Hypersensitivity (including skin conditions such as 
tinea versicolor, dermatitis, rosacea) 
23 1.383
Urinary Tract Infection 1 0.06
Malignancies* 0 ---
Autoimmunity* 0 ---
Infections, Other*# 11 0.666
Total: 69 4.18
Medical Conditions
Table II:  Incidence data, ISS Program, Expeditions 1 to 28/29; 37 ISS crewmembers; 
total flight duration 6072 days/16.63 person years.  
Source JSC Epidemiology Group: A. Babiak-Vazquez, Sara Mason and Jessica Garcia. 
*Indicates additional conditions or symptoms categorized, beyond the original 13 IMM conditions.  
#Additional infectious processes not characterized within other categories such as lymphadenitis, 
lymphadenopathy, mild fever and intestinal problems with such symptoms as diarrhea, excessive 
intestinal gas and bloating.
ISS Incidence Tabulation Data tabulated from 37 long-duration ISS crewmembers 
(Exp. 1-28/29; totals 16.63 person flight years)
9 crew (24%)
8 crew (22%)
20 crew (54%)
42 Reported Events
Additional Crew Incidence Observations
Breakdown of 69 in-flight medical events in the context 
of clinical significance:  significant versus non-significant 
in 37 six-month ISS crew-missions.
Significant Events
20 crew (54%)
42 Reported Events Non-Significant Events
8 crew (22%)
No Reported Events
9 crew (24%)
Breakdown of 42 reported significant medical events reported in 20 of 37 ISS 
crewmembers.  Relative percentages among the reported events are indicated.
Additional Crew Incidence Observations
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▪ Skin conditions account for 7% of out-patient visits to primary 
care providers in the U.S.
▪ In 2001, there were 37.9 visits to office-based dermatologists 
for skin conditions in the U.S. (0.136 visits/person-year)
▪ In 2001, there were 12.1 million visits to physician offices for 
skin rashes in the U.S. (0.044 visits/person-year)
References: -National Ambulatory Medical Care Survey: 2001 Summary
-U.S. Census Bureau, Statistical Abstract of the United States: 2001
Terrestrial Incidence of Skin Rashes
Case Study ISS Astronaut
• Typical busy pre-mission training schedule
• Launch on Soyuz;  docking to ISS + 2 days
• 191 day mission onboard ISS
• 3 Shuttle dockings, 2 Progress dockings, 1 
ATV docking
• 5 EVA activities (12 Shuttle EVA)
• Typically busy mission schedule
• Landing on Soyuz, GCTC 1 week
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                     MEDICATIONS KEY
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Peripheral Blood Cytokine mRNA Expression
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Plasma Cytokine Profile
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Circadian Rhythm of Salivary Cortisol
L-180 L-45 EAR MID LATE R+0 R+30
IL-1b 11828 16269 114 665 247 442 10918
TNFa 3651 5045 1319 1810 5382 2077 4405
IL-6 8890 8673 2785 6301 8625 7005 8732
IL-8 12165 11408 11708 12005 12131 12014 11706
Mitogen Stimulated Cytokine Profiles (pg/ml)
anti-CD3+CD28 (48hr)
L-180 L-45 EAR MID LATE R+0 R+30
IFNg 1794 14610 912.36 341.64 5607 1936 13754
IL-2 740.75 674.44 1479 865.92 370.83 109.96 1374
IL-4 169.08 185.22 152.54 137.16 149.46 117.85 176.36
IL-5 31.68 29.16 31.09 16.96 15.62 16.45 29.39
IL-10 3163 3080 152.77 184.68 150.93 551.93 3377
IL-12p70 5.85 7.48 3.89 2.38 22.97 3.24 8.13
Mitogen Stimulated Cytokine Profiles (pg/ml)
anti-CD3+CD28 (48hr)
L-180 L-45 EAR MID LATE R+0 R+30
IL-13 284.07 738.17 362.64 184.89 812.5 659.26 1543
IL-7 25.81 21.27 20.23 23.19 25.81 23.63 25.71
GM-CSF 1092 985.34 686.15 986.86 1059 462.01 1645
Mitogen Stimulated Cytokine Profiles (pg/ml)
anti-CD3+CD28 (48hr)
Conclusions
• Spaceflight is associated with persistent immune system 
dysregulation and latent herpesvirus reactivation
• There is some degree of clinical incidence onboard ISS, with 
rashes among the most frequently reported symptomology
• Case study astronaut developed novel allergy symptoms and 
atopic eczema on mission day 17 and never fully resolved
• Supplies of anti-histamines and topical steroids were 
periodically exhausted
• Symptoms generally correlated with stressful mission events
• Case study subject displayed typical depressions in T cell 
function, cytokine dysregulation
• Case study subject shed EBV through mid-mission, and VZV late 
in-flight through R+30
Conclusions
• Spaceflight is a granular experience consisting of 
chronic stress interspersed with periodic acute 
stressors
• Immune dysregulation during flight appears to 
be polar, with some adaptive processes 
depressed (T cell function, HV shedding); 
whereas some innate processes are elevated 
(inflammation, hypersensitivity reactions)
• Exploration immune countermeasures must be 
considered carefully from among multisystem 
(exercise, etc.), benign supplements (probiotics, 
etc.) to pharmacological interventions (beta 
blockers, etc.)
